Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial
November 12, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
Focus will be on Milestones for Development and Commercialization CAP-1002 Therapy for Duchenne Muscular Dystrophy LOS ANGELES, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:...
FibroGen Reports Third Quarter 2018 Financial Results
November 08, 2018 16:02 ET
|
FibroGen, Inc
—Roxadustat New Drug Applications under Review in China and Japan——Phase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019——Conference Call Today at 5:00 p.m. Eastern...
Capricor Therapeutics to Present Corporate Overview and Poster at Action Duchenne International Conference
November 08, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
Research Found Exosomes Increased Exercise Capabilities and Muscle Activity in a Mouse Model of Duchenne Muscular Dystrophy LOS ANGELES, Nov. 08, 2018 (GLOBE NEWSWIRE) -- During the Action...
Capricor Therapeutics to Participate in Upcoming Conferences
October 22, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
Presentations to Focus on Company’s Exosome-based and Duchenne Muscular Dystrophy Therapies LOS ANGELES, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Linda Marbán, Ph.D, CEO of Capricor Therapeutics, Inc....
Capricor Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa
October 03, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
LA JOLLA, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) will provide a presentation at the 2018 Cell & Gene Meeting on the Mesa today on its cell therapy,...
Capricor Therapeutics Presents Results of Studies of CAP-2003 at Gordon Research Conference on Extracellular Vesicles
August 21, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Aug. 21, 2018 (GLOBE NEWSWIRE) -- At the Gordon Research Conference on Extracellular Vesicles in Newry, Maine, Capricor Therapeutics (NASDAQ: CAPR) presented research findings on the...
Capricor Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 09, 2018 16:00 ET
|
Capricor Therapeutics, Inc.
To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology...
FibroGen Reports Second Quarter 2018 Financial Results
August 07, 2018 16:02 ET
|
FibroGen, Inc
Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018 Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced Unresectable Pancreatic...
Capricor Therapeutics and PPMD to Host Webinar for Duchenne Muscular Dystrophy Community on July 18
July 13, 2018 09:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, July 13, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) and Parent Project Muscular Dystrophy (PPMD) will host a webinar at 1 p.m. ET on July 18 to provide information...
Capricor Therapeutics to Present at PPMD Annual Conference
June 28, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, June 28, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics’ (NASDAQ:CAPR) chief medical officer, Deborah Ascheim, M.D., will present a corporate overview at the Parents Project Muscular...